第 29 届年度前列腺癌基金会 (PCF) 科学务虚会于 2022 年 10 月 27 日至 29 日在加利福尼亚州卡尔斯巴德的 Omni La Costa 度假村举行。这是有史以来第一次混合 PCF 静修会。年度 PCF 科学静修会是一次著名的国际科学聚会，重点关注前列腺癌基础、转化和临床研究方面的开创性、未发表和有影响力的研究。它还涵盖了对影响前列腺癌研究和患者护理具有强大潜力的相关领域的研究。2022 年 PCF 务虚会重点关注的关键研究领域包括：(i) 分子和基因组因素对前列腺癌差异的贡献； (ii) 新颖的临床试验更新； (iii) 原发性前列腺癌的教训； (iv) 单细胞研究的教训； (v) 前列腺癌的遗传、表观遗传、表观转录和翻译后机制以及临床异质性； (vi) 神经内分泌和谱系可塑性前列腺癌的生物学； (vii) 下一代前列腺癌治疗诊断和联合疗法； (viii) 靶向磷酸肌醇 3-激酶途径的生物学和治疗潜力； (ix) 联合免疫调节疗法治疗前列腺癌； (x) 用于肿瘤学的新型γδ（γδ）T细胞治疗平台； (xi) 其他癌症的教训。本文总结了 2022 年 PCF 科学静修会的演讲。通过传播这些知识，我们希望加深对当前研究格局的理解，并指导前列腺癌研究和患者护理的未来进步。© 2023 Wiley periodicals LLC。

The 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 27 to 29, 2022, at the Omni La Costa Resort in Carlsbad, CA. This was the first-ever hybrid PCF Retreat.The Annual PCF Scientific Retreat is a prominent international scientific gathering centered on groundbreaking, unpublished, and influential studies in basic, translational, and clinical prostate cancer research. It also covers research from related fields with a strong potential for influencing prostate cancer research and patient care.Key areas of research that were focused on at the 2022 PCF Retreat included: (i) the contributions of molecular and genomic factors to prostate cancer disparities; (ii) novel clinical trial updates; (iii) lessons from primary prostate cancer; (iv) lessons from single-cell studies; (v) genetic, epigenetic, epitranscriptomic and posttranslational mechanisms and clinical heterogeneity in prostate cancer; (vi) biology of neuroendocrine and lineage-plastic prostate cancer; (vii) next generation prostate cancer theranostics and combination therapies; (viii) the biology and therapeutic potential of targeting phosphoinositide 3-kinases pathways; (ix) combining immunomodulatory treatments for prostate cancer; (x) novel gamma delta (γδ) T-cell therapy platforms for oncology; and (xi) lessons from other cancers.This article provides a summary of the presentations from the 2022 PCF Scientific Retreat. By disseminating this knowledge, we hope to enhance our understanding of the present research landscape and guide future strides in both prostate cancer research and patient care.© 2023 Wiley Periodicals LLC.